Senolytic Treatment with Dasatinib and Quercetin Confirmed to Reduce the Burden of Senescent Cells in Human Patients

Setting aside the mice genetically engineered to destroy senescent cells, the combination of dasatinib and quercetin is the oldest of the senolytic treatments used in animal studies. Senolytic therapies are those that selectively destroy senescent cells in old tissues in order to produce rejuvenation, turning back the progression of numerous age-related conditions. Unusually for early stage research, these initial senolytics are actually quite effective, considered in the grand scheme of things. Thus they have moved directly to human trials in some cases. The first data on their ability to produce the same outcomes in humans as in mice emerged this year, and more data will continue to roll out over the next few years as the first trials run and complete. The results reported in today’s

from http://besthealthnews.com/2019/09/senolytic-treatment-with-dasatinib-and-quercetin-confirmed-to-reduce-the-burden-of-senescent-cells-in-human-patients/?utm_source=rss&utm_medium=rss&utm_campaign=senolytic-treatment-with-dasatinib-and-quercetin-confirmed-to-reduce-the-burden-of-senescent-cells-in-human-patients

from
https://healthnews010.tumblr.com/post/187813246018